These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15307572)

  • 21. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antiretroviral therapy. NNRTI (non-nucleoside reverse transcriptase inhibitor)].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():14-6. PubMed ID: 10863304
    [No Abstract]   [Full Text] [Related]  

  • 23. Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.
    Zhou J; Phanupak P; Kiertiburanakul S; Ditangco R; Kamarulzaman A; Pujary S;
    J Acquir Immune Defic Syndr; 2006 Dec; 43(4):501-3. PubMed ID: 17099317
    [No Abstract]   [Full Text] [Related]  

  • 24. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 25. First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
    AIDS Alert; 1998 Nov; 13(11):121-4. PubMed ID: 11365967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-related neutropaenia exacerbated by efavirenz.
    Healy BJ; Freedman AR
    HIV Med; 2006 Mar; 7(2):129-31. PubMed ID: 16420258
    [No Abstract]   [Full Text] [Related]  

  • 27. Novel approaches for the treatment of HIV.
    Arroyo HT
    Newsline People AIDS Coalit N Y; 1998 Mar; ():16-7. PubMed ID: 11367450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038
    [No Abstract]   [Full Text] [Related]  

  • 29. Efavirenz-induced photoallergic dermatitis in HIV.
    Treudler R; Husak R; Raisova M; Orfanos CE; Tebbe B
    AIDS; 2001 May; 15(8):1085-6. PubMed ID: 11400003
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new HAART on the horizon says the proof is in the potency.
    AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
    Fraaij PL; Neubert J; Bergshoeff AS; van Rossum AM; Hartwig NG; Schroten H; Korn K; Burger DM; de Groot R; Niehues T
    Antivir Ther; 2004 Apr; 9(2):297-9. PubMed ID: 15134193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

  • 35. HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
    Meyer-Kleinmann J
    Infection; 2004 Jun; 32(3):7. PubMed ID: 15230276
    [No Abstract]   [Full Text] [Related]  

  • 36. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haemolytic anaemia associated with efavirenz.
    Freercks RJ; Mehta U; Stead DF; Meintjes GA
    AIDS; 2006 May; 20(8):1212-3. PubMed ID: 16691081
    [No Abstract]   [Full Text] [Related]  

  • 39. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.